Respiratory Infections

The shot will be its NanoFlu/NVX-CoV2373 vaccine using the company’s Matrix-M adjuvant platform.

Past research has observed links between cardiovascular disease and influenza infection. Vaccination may benefit at-risk patients.

The first participants were vaccinated in the study with Pfizer’s respiratory syncytial virus (RSV) investigational vaccine candidate in adults ages 60 or older.

Persons living with HIV are susceptible to TB and also appear at increased risk for infecting strains acquiring rifampicin-resistance.

An Israel study estimates vaccinated persons' risk of side effects including myocarditis, relative to the risk brought on by SARS-CoV-2 infection.

David Weber, MD, MPH, explains what portion of the population may buy into the newly approved Pfizer-BioNTech vaccine.

Kevin J. Downes, MD, and Contagion® Section Editor Conan MacDougall, PharmD, MAS, BCPS, BCIDP, discuss these important topics as another season approaches.

The full approval for BNT162b2 will afford physicians greater prescribing capability, and will likely drive workplace vaccine mandates.

The evolution of the major variants, including the delta mutation.

The Biden administration reportedly hopes for FDA-authorized booster doses for the adult general population in the next month.

While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.

The US is targeting a possible Fall rollout of publicly available doses, yet experts debate their current necessity.

A quartet of infectious disease, vaccinology, and virology experts share thoughts on the FDA's newest emergency authorization for COVID-19 mRNA vaccines.

"Humans dislike change, especially when it is rapid, unexpected, or negative. Delta is all 3."

A look at the COVID-19 driven factors for this upcoming influenza season, from reopening classrooms to reduced mutation chances.

What risks and benefits need to be considered with the return of in-person classes?

FluGen announced its vaccine candidate, Bris2007 M2SR, induced neutralizing antibodies against infection and illness following a challenge with an antigenically distinct virus.

A clinical decision support (CDS) strategy including a default influenza vaccine order for eligible patients, a nursing script using a presumptive strategy, and education for clinicians, was associated with significant improvement in vaccination rates among hospitalized children, a new study showed.

Pfizer and Moderna will include children aged 5-11 years old in ongoing trials to speak toward risk of rare adverse events observed in other young recipients.

94% of the participants developed IgG antibodies against the virus 3 weeks after administration.

A group of personnel at a veterans administration medical center (VAMC)) did a drive-thru to help bolster vaccination amongst coworkers.

A meeting between developers and federal experts was inconclusive to the necessity of a third mRNA dose for COVID-19.

The announcement aligns with an FDA and CDC statement against the need for booster doses.

Plus: how could the COVID-19 testing market boom improve public flu awareness?

COVID-19 response restrained flu outbreaks last year. An expert explains his concern that won't be enough this winter.

An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.

New ASM data show indoor environments are associated with quick and frequent pathogen contamination of the common respiratory device.

An interview with a study author on unique associations between county infrastructures and COVID-19 fatality rates.

The device may help clinicians differentiate between past infections and co-infections during the upcoming flu season.

Examining pharmacological management in COVID-19 patients with ARDS requiring antifungal therapy during extracorporeal life support.